Pfizer’s Safe House: Peter Honig Builds A Regulatory Model For The Future
Executive Summary
In Vivo talks to Pfizer SVP for worldwide safety and regulatory Peter Honig on the challenges of establishing – and then maintaining – the confidence of a diverse array of constituencies in the safe, effective use of medicines for a $50 billion business.